Robin Kate Kelley

33PUBLICATIONS
233CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursMolecular targetsCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Aug 14, 2026
A Phase II Trial of Pembrolizumab plus Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Biliary Cancer.

|Jun 10, 2026
Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.

|Feb 27, 2026
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study.

Stephen L Chan, Thomas Yau, Robin K Kelley

|Dec 29, 2025
MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response.

Jinkai Wan, Hatice Duygu Saatcioglu, Haley Ellis

|Dec 19, 2025
Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials.

Fen Saj, Felicity K Namayanja, Lianchun Xiao

|Dec 08, 2025
T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma.

Robin K Kelley, Young Lee, James Conway

Pageof 6

Frequent Collaborators

9 joint publications

Ghassan K Abou-Alfa

6 joint publications

John D Gordan

4 joint publications

Ann-Lii Cheng

4 joint publications

Milind M Javle